CRA-2059 (TFA)
CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ) [1][2].
Product Specifications
UNSPSC
12352005
Target
Ser/Thr Protease
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cra-2059-tfa.html
Purity
99.88
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC(NC1=CC=C(CNC(N2CCN(C(O[C@@H]3COC4[C@H](OC(N5CCN(C(NCC6=CC=C(NC(N)=N)C=C6)=O)CC5)=O)COC34)=O)CC2)=O)C=C1)=N.FC(F)(F)C(O)=O
Molecular Formula
C36H47F3N12O10
Molecular Weight
864.83
References & Citations
[1]Tremaine WJ, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059) : an open-label pilot study. Aliment Pharmacol Ther. 2002;16 (3) :407-413.|[2]Selwood T, et al. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. Biol Chem. 2003;384 (12) :1605-1611.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![[KD] Presenilin 1 Rabbit mAb](https://cdn.genprice.uk/genprice/uk/genprice3.webp)
